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stepdown procedure allowed for statistical testing of survival (nomi-
nal P<0.025 for increased survival; <0.012 for decreased survival) if 
change in Hb was signiﬁcant at P<0.05. 
Results: Efﬁcacy and safety endpoints are presented in the table and 
graph.
Conclusions: DA administered 300µg QW followed by 300µg Q3W 
signiﬁcantly lessened reductions in Hb and signiﬁcantly reduced the in-
cidence of transfusions compared with placebo. There have been recent 
concerns relating to poorer survival in studies that targeted higher Hb 
levels; however, no difference in overall or progression-free survival 
was observed between the DA and placebo groups in this study.
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Background: Historically, approximately one third of patients with 
advanced lung cancer have developed bone metastases. Over time, 
malignant bone disease results in potentially disabling skeletal-related 
events (SREs) such as pathologic fracture, spinal cord compression, 
severe bone pain requiring radiotherapy, the requirement for orthopedic 
surgery, and hypercalcemia of malignancy. Within the past decade, 
therapeutic advances have produced signiﬁcant improvements in sur-
vival for patients with NSCLC. Therefore, we evaluated whether bone 
metastases have time to manifest in SREs within the lifetime of patients 
with NSCLC using a registration trial database from a large, random-
ized, controlled trial in patients with bone metastases from NSCLC or 
other solid tumors (Rosen LS, et al. Cancer. 2004;100:2613-2621).
Methods: A retrospective evaluation of SREs and survival was per-
formed on patients with NSCLC who were randomized to treatment 
with either zoledronic acid or placebo for up to 21 months (n = 378). 
All patients received concomitant antineoplastic therapy. Skeletal mor-
bidity was also analyzed using a robust survival-adjusted cumulative 
mean function.
Results: The trial in patients with bone metastases from solid tumors 
was conducted from August 1998 to January 2002, and the NSCLC 
patients had been diagnosed with bone metastases an average of 
approximately 4 months before enrollment. Median survival was 
approximately 6 months for these patients. However, within the ﬁrst 
6 months of this study approximately 50% of patients in the placebo 
group had experienced ≥ 1 SRE, more than 20% experienced ≥ 2 SREs, 
and more than 5% experienced ≥ 3 SREs. These analyses were adjusted 
for the effects of survival on skeletal morbidity. In the placebo group, 
the survival-adjusted cumulative mean incidence of events at 6 months 
was approximately 0.9 SREs per patient and approximately 0.5 events 
of radiation to bone per patient. 
Conclusions: These exploratory analyses of data from a multicenter in-
ternational trial show that patients with bone metastases from NSCLC 
experience skeletal morbidity within their lifetimes. Since this trial, 
additional treatment options have been developed that may prolong sur-
vival in this setting. As a result, increasing proportions of patients may 
develop SREs, which could decrease their quality of life and undermine 
their functional independence. Although these 6-month analyses were 
not statistically powered to detect treatment effects in the NSCLC stra-
tum, the results were consistent with the previously published analyses 
for the overall trial population in which zoledronic acid signiﬁcantly 
reduced the incidence of and delayed the onset of SREs during up to 21 
months of treatment.
